# IN8bio (INAB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/INAB
## Company Profile
- Ticker: INAB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 0.9985 USD
- Market cap: 14959872.72 USD
- Last updated: 2026-08-12
## Business Overview
### Gamma-Delta T-Cell Therapies
IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells.
### Glioblastoma Program
The company's clinical work in glioblastoma evaluates gamma-delta T cells alongside standard treatment, with survival and disease-control data informing potential regulatory discussions.
### T-Cell Engager Platform
INB-619 is a next-generation gamma-delta T-cell engager progressing through IND-enabling studies. The broader engager platform is intended to create off-the-shelf approaches that recruit endogenous immune cells.
## Why The Stock Is Moving

As of Aug 12, 2026, INAB closed down 4.90% at $0.9985. No new same-company headline was identified in the current news window.

## Future Catalysts

- Updated median overall-survival data from the glioblastoma program at ASCO 2026.
- Initial animal data for INB-619 and the gamma-delta T-cell engager platform during 2026.

## Recent News
- 2026-08-10 20:01 EST — [IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/INAB/in8bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-70299eb4) — Source: IN8bio
- 2026-08-06 20:01 EST — [IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/INAB/in8bio-reports-second-quarter-2026-financial-results-and-recent-business-highlig-81c5698f) — Source: IN8bio
- 2026-07-09 12:00 EST — [IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma](https://biopharmsignal.com/news/INAB/in8bio-announces-publication-in-the-journal-of-clinical-oncology-demonstrating-d-4c0f417a) — Source: IN8bio
- 2026-06-03 12:30 EST — [IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies](https://biopharmsignal.com/news/INAB/in8bio-announces-publication-in-nature-communications-highlighting-advances-in-gamma-delta-t-cell-engineering-and-combination-therapies) — Source: IN8bio
- 2026-06-01 12:30 EST — [IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026](https://biopharmsignal.com/news/INAB/in8bio-presents-updated-overall-survival-data-surpassing-19-5-months-for-deltex-dri-in-newly-diagnosed-glioblastoma-at-asco-2026) — Source: IN8bio